Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients - 03/02/24

Doi : 10.1016/j.jinf.2023.11.008

Santiago Grau ^{^{1
These authors contributed equally.}}
Department of Pharmacy, Hospital del Mar, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain

José Miguel Vela ^{^{1
These authors contributed equally.}}
Welab Barcelona, Parc Científic de Barcelona, Barcelona 08028, Spain

Alba Gurt ^{^{1
These authors contributed equally.}}
CAP Vila Olímpica, Parc Sanitari Pere Virgili, Barcelona, Spain

Jaime Barceló-Vidal ^{^{1
These authors contributed equally.}}
Department of Pharmacy, Hospital del Mar, 08003 Barcelona, Spain

Fabiola Ojeda
Rheumatology Service, Hospital del Mar, Barcelona, Spain

Iago López
IMIM (Hospital Del Mar Medical Research Institute), PRBB, Barcelona, Spain

Laura Gómez-García, María Isabel Loza ^{^{2
These authors equally supervised this work.}}
Health Research Institute of Santiago de Compostela (IDIS), Drug Screening and Pharmacogenomics Platform/BioFarma Research Group, CIMUS Research Center, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain

Elena Martín-García ^{^{2
These authors equally supervised this work.}}
IMIM (Hospital Del Mar Medical Research Institute), PRBB, Barcelona, Spain
Laboratory of Neuropharmacology-Neurophar, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Departament de Psicobiologia i Metodologia de les Ciències de la Salut, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

Rafael Maldonado ⁎, ^{^{2
These authors equally supervised this work.}}
IMIM (Hospital Del Mar Medical Research Institute), PRBB, Barcelona, Spain
Laboratory of Neuropharmacology-Neurophar, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain

^*Correspondence to: Department of Experimental and Health Sciences, Pompeu Fabra University, Dr. Aiguader 88, 08003 Barcelona, Spain.Department of Experimental and Health Sciences, Pompeu Fabra UniversityDr. Aiguader 88Barcelona08003Spain
Jordi Monfort ^{^{2
These authors equally supervised this work.}}
Rheumatology Service, Hospital del Mar, Barcelona, Spain
IMIM (Hospital Del Mar Medical Research Institute), PRBB, Barcelona, Spain

SIGMA Group^³
A list of authors and their affiliations appears in PubMed's Acknowledgments and Collaborators section.

Le texte complet de cet article est disponible en PDF.

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Le texte complet de cet article est disponible en PDF.

Plan

Funding

Export

Vol 88 - N° 2

P. 187-190 - février 2024 Retour au numéro

Article précédent

How do successive vaccinations and SARS-CoV-2 infections impact humoral immunity dynamics: An 18-month longitudinal study
A.N. Diep, J. Schyns, C. Gourzones, E. Goffin, I. Papadopoulos, S. Moges, F. Minner, O. Ek, G. Bonhomme, M. Paridans, N. Gillain, E. Husson, M. Garigliany, G. Darcis, C. Saegerman, D. Desmecht, M. Guillaume, Donneau A.F., F. Bureau, L. Gillet

| Article suivant

Machine learning-based colistin resistance marker screening and phenotype prediction in Escherichia coli from whole genome sequencing data
Yingxin Tian, Di Zhang, Fangyuan Chen, Guanhua Rao, Ying Zhang

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients - 03/02/24

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL